Screener
4D Molecular Therapeutics FDMT Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
FAQ
- What is 4D Molecular Therapeutics's free cash flow?
- 4D Molecular Therapeutics (FDMT) reported free cash flow of -$68.13M in Q1 2026.
- How has 4D Molecular Therapeutics's free cash flow changed year-over-year?
- 4D Molecular Therapeutics's free cash flow decreased by 40.8% year-over-year, from -$48.39M to -$68.13M.
- What is the long-term trend for 4D Molecular Therapeutics's free cash flow?
- Over 3 years (2021 to 2024), 4D Molecular Therapeutics's free cash flow has grown at a 20.9% compound annual growth rate (CAGR), from -$78.24M to -$138.37M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about 4D Molecular Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude